Search Results - "KRAFT, K"

Refine Results
  1. 1

    The Nephrotoxicity of Vancomycin by Filippone, EJ, Kraft, WK, Farber, JL

    Published in Clinical pharmacology and therapeutics (01-09-2017)
    “…Vancomycin use is often associated with nephrotoxicity. It remains uncertain, however, to what extent vancomycin is directly responsible, as numerous potential…”
    Get full text
    Journal Article
  2. 2

    Buprenorphine in Neonatal Abstinence Syndrome by Kraft, Walter K.

    Published in Clinical pharmacology and therapeutics (01-01-2018)
    “…Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long‐acting opioid…”
    Get full text
    Journal Article
  3. 3

    Effects of gradual differences in trypsin inhibitor activity on the estimation of digestible amino acids in soybean expellers for broiler chickens by Kuenz, S., Thurner, S., Hoffmann, D., Kraft, K., Wiltafsky-Martin, M., Damme, K., Windisch, W., Brugger, D.

    Published in Poultry science (01-04-2022)
    “…The present study investigated the effect of varying trypsin inhibitor activity (TIA) in differently processed soybean expellers on apparent prececal amino…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Environmental algal phage isolates and their impact on production potential for food and biofuel applications by Kraft, K., Alum, A., Abbaszadegan, M.

    Published in Journal of applied microbiology (01-01-2020)
    “…Aims The United States Department of Energy is aiming to bring microalgal biofuels into commercial use by 2030 at the price of $3 per gasoline gallon…”
    Get full text
    Journal Article
  6. 6

    Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS) by Mangat, A.K., Schmölzer, G.M., Kraft, W.K.

    Published in Seminars in fetal & neonatal medicine (01-04-2019)
    “…Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants develop after intrauterine maternal drug exposure. All infants with…”
    Get full text
    Journal Article
  7. 7

    Tumor necrosis factor inhibitors in psoriatic arthritis by Mantravadi, Santhi, Ogdie, Alexis, Kraft, Walter K

    Published in Expert review of clinical pharmacology (03-08-2017)
    “…Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors…”
    Get more information
    Journal Article
  8. 8
  9. 9

    Ethanol Pharmacokinetics in Neonates and Infants by Marek, Elizabeth, PharmD, Kraft, Walter K., MD

    Published in Current therapeutic research (01-12-2014)
    “…Abstract Introduction Ethanol has been used for years in neonatal and infant liquid medications, yet the pharmacokinetics, pharmacodynamics, and safety of…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial by Lam, Kevin, Kraft, Walter K., Zhan, Tingting, Lam, Edwin

    Published in Clinical and translational science (01-03-2024)
    “…Transgender women may have concerns of drug interactions between feminizing hormone therapy (FHT) and antiretrovirals, leading to nonadherence. This…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Development of an abbreviated symptom score for the neonatal abstinence syndrome by Chervoneva, I., Adeniyi-Jones, S. C., Blanco, F., Kraft, W. K.

    Published in Journal of perinatology (01-07-2020)
    “…Objective We sought a shortened MOTHER neonatal abstinence syndrome (NAS) and Finnegan score that would retain comparable performance characteristics of the…”
    Get full text
    Journal Article
  14. 14

    Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome by Kraft, Walter K, Adeniyi-Jones, Susan C, Chervoneva, Inna, Greenspan, Jay S, Abatemarco, Diane, Kaltenbach, Karol, Ehrlich, Michelle E

    Published in The New England journal of medicine (15-06-2017)
    “…In this single-center trial involving term infants with in utero opioid exposure, the use of sublingual buprenorphine resulted in a shorter duration of…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy by Lam, Edwin, Lien, Yi Ting (Kayla), Kraft, Water K, Piraino, Beth, Vozmediano, Valvanera, Schmidt, Stephan, Zhang, Jingjing

    Published in Peritoneal Dialysis International (01-07-2020)
    “…Intraperitoneal vancomycin is the first-line therapy in the management of peritoneal dialysis (PD)-related peritonitis. However, due to the paucity of data,…”
    Get full text
    Book Review Journal Article
  17. 17

    Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant by Kraft, Walter K., MD, Stover, Megan W., MD, Davis, Jonathan M., MD

    Published in Seminars in perinatology (01-04-2016)
    “…Abstract Opioid use in pregnancy has increased dramatically over the past decade. Since prenatal opioid use is associated with numerous obstetrical and…”
    Get full text
    Journal Article
  18. 18

    Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome by Jones, Hendrée E., PhD, Kraft, Walter K., MD

    Published in Clinics in perinatology (01-06-2019)
    “…When opioid misuse rises in the United States, pregnant women and their neonates are affected. This article summarizes the use of Food and Drug…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults by Min, K. Chris, Kraft, Walter K., Bondiskey, Phung, Colón‐González, Francheska, Liu, Wen, Xu, Jialin, Panebianco, Deborah, Mixson, Lori, Dockendorf, Marissa F., Matthews, Catherine Z., Boinpally, Ramesh

    Published in Clinical and translational science (01-03-2021)
    “…Atogepant is a potent, selective, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for migraine prevention. The chemical…”
    Get full text
    Journal Article